Therapy Trends KOL Insight: Non-Small Cell Lung Cancer 
How do KOLs believe the integration of PD-1/L1 inhibitors into attempts to cure NSCLC could shift the treatment paradigm? What underpins oncologists' hopes that Roche's pipeline tiragolumab/Tecentriq combination could challenge Merck & Co.'s Keytruda in PD-L1-high NSCLC? What opportunities are there for AstraZeneca's Tagrisso in the adjuvant treatment of EGFR-driven NSCLC? US and European KOLs critically assess the prospects of launched and pipeline therapies.
|Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.|
Key questions answered
- How do KOLs expect AstraZeneca and Daiichi Sankyo's Enhertu to change the standard of care for patients with HER2 mutations?
- Do KOLs expect Takeda's Alunbrig, Xcovery's ensartinib or Pfizer's Lorbrena/Lorviqua to threaten Roche's Alecensa in ALK-translocated NSCLC?
- Why do KOLs believe Roche's Tecentriq and Bristol Myers Squibb's Opdivo/Yervoy will not significantly challenge Merck & Co.'s Keytruda in the non-oncogene-driven, metastatic first-line setting?
- How do experts see the future for Eli Lilly's Retevmo and Blueprint Medicines/Roche's Gavreto in RET-driven NSCLC?
Examples of Therapies Covered
Partial List of Participating KOLs
|We engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.|
|Our-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.|
|Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.|
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.